Front Row Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.56K Hold
20
﹤0.01% 489
2025
Q4
$2.44K Hold
20
﹤0.01% 480
2025
Q3
$2K Hold
20
﹤0.01% 487
2025
Q2
$1.66K Hold
20
﹤0.01% 476
2025
Q1
$1.62K Hold
20
﹤0.01% 453
2024
Q4
$1.8K Hold
20
﹤0.01% 448
2024
Q3
$1.98K Hold
20
﹤0.01% 446
2024
Q2
$1.85K Hold
20
﹤0.01% 856
2024
Q1
$1.9K Hold
20
﹤0.01% 850
2023
Q4
$1.79K Hold
20
﹤0.01% 418
2023
Q3
$1.46K Hold
20
﹤0.01% 844
2023
Q2
$2K Hold
20
﹤0.01% 830
2023
Q1
$2K Hold
20
﹤0.01% 845
2022
Q4
$2K Hold
20
﹤0.01% 810
2022
Q3
$2K Hold
20
﹤0.01% 843
2022
Q2
$1K Hold
20
﹤0.01% 910
2022
Q1
$2K Hold
20
﹤0.01% 882
2021
Q4
$2K Hold
20
﹤0.01% 896
2021
Q3
$3K Hold
20
﹤0.01% 835
2021
Q2
$2K Hold
20
﹤0.01% 893
2021
Q1
$3K Hold
20
﹤0.01% 835
2020
Q4
$3K Hold
20
﹤0.01% 798
2020
Q3
$3K Hold
20
﹤0.01% 795
2020
Q2
$2K Hold
20
﹤0.01% 885
2020
Q1
$2K Buy
+20
New +$1.77K ﹤0.01% 859

Other funds holding XBI

Front Row Advisors's XBI Position: Q1 2026 in Review

Front Row Advisors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 20 shares worth $2.56K. The position accounts for ﹤0.01% of the portfolio, ranked #489.

Front Row Advisors first reported a position in XBI in Q1 2020 and has held it in 25 quarters since. The position peaked at $3K in Q3 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Front Row Advisors held 20 shares of State Street SPDR S&P Biotech ETF worth $2.56K as of Q1 2026.
  • Front Row Advisors left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Front Row Advisors's portfolio in Q1 2026, its #489 holding.
  • Front Row Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and has held it in 25 quarters since.
  • Front Row Advisors's State Street SPDR S&P Biotech ETF position peaked at $3K in Q3 2021.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.